EGFR and neoplasm: While this preliminary analysis provides some encouraging evidence for the potential clinical utility of scASTRAL, it is crucial to recognize that further validation studies involving larger datasets of patients treated with anti-EGFR therapy are essential to fully evaluate the model’s performance on more complex data as primary tumour’s biopsy.